+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Respiratory Drugs Market 2018-2022 - Product Image

Global Respiratory Drugs Market 2018-2022

  • ID: 4704207
  • Report
  • November 2018
  • Region: Global
  • 113 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • MORE
The high cost of respiratory disease management is expected to drive growth in the respiratory drugs market. The high cost of respiratory disease management has led the organizations such as the Lung Foundation Australia to demand support and funding from the government to reduce the cost. The analysts have predicted that the respiratory drugs market will register a CAGR of almost 6% by 2022.

Market Overview

Increase in incidence and prevalence of different types of respiratory diseases

Globally, respiratory diseases are a key cause of mortality and disease burden. Numerous types of respiratory diseases are on the rise, thereby pushing growth in the respiratory drugs market.

Patient non-adherence treatment

Non-adherence to treatment is particularly problematic for asthma and COPD disease management due to heterogeneous patient population. Device switching symptoms variability, and comorbidities are responsible for suboptimal adherence rates.

For the detailed list of factors that will drive and challenge the growth of the respiratory drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including AstraZeneca and GlaxoSmithKline, the competitive environment is quite intense. Factors such as the high cost of respiratory disease management and the increase in incidence and prevalence of different types of respiratory diseases, will provide considerable growth opportunities to respiratory drugs manufactures. AstraZeneca, GlaxoSmithKline, Novartis, and Merck are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. Several respiratory drug companies are focused on evolving new respiratory drugs with the entry of biologics and biosimilars for promising options for respiratory disease management.’
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF RESPIRATORY DISEASE
  • Segmentation by type of respiratory disease
  • Comparison by type of respiratory disease
  • Asthma - Market size and forecast 2017-2022
  • COPD - Market size and forecast 2017-2022
  • Allergic rhinitis - Market size and forecast 2017-2022
  • Cystic fibrosis - Market size and forecast 2017-2022
  • Idiopathic pulmonary fibrosis - Market size and forecast 2017-2022
  • Other respiratory disorders - Market size and forecast 2017-2022
  • Market opportunity by type of respiratory disease
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • High cost of respiratory disease management
  • Availability of biologics and biosimilars
  • High use of complementary and alternative medicines
  • Entry of generics
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market: Market size
Exhibit 02: Global pharmaceuticals market: Segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III development
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global respiratory drugs market - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global respiratory drugs market - Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global respiratory drugs market by type of respiratory disease - Market share 2017-2022 (%)
Exhibit 20: Comparison by type of respiratory disease
Exhibit 21: Global respiratory drugs market by asthma - Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Global respiratory drugs market by asthma - Year over year growth 2018-2022 (%)
Exhibit 23: Global respiratory drugs market by COPD - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Global respiratory drugs market by COPD - Year over year growth 2018-2022 (%)
Exhibit 25: Global respiratory drugs market by allergic rhinitis - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global respiratory drugs market by allergic rhinitis - Year over year growth 2018-2022 (%)
Exhibit 27: Global respiratory drugs market by cystic fibrosis - Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global respiratory drugs market by cystic fibrosis - Year over year growth 2018-2022 (%)
Exhibit 29: Global respiratory drugs market by idiopathic pulmonary fibrosis - Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Global respiratory drugs market by idiopathic pulmonary fibrosis - Year over year growth 2018-2022 (%)
Exhibit 31: Global respiratory drugs market by other respiratory disorders - Market size and forecast 2017-2022 ($ bn)
Exhibit 32: Global respiratory drugs market by other respiratory disorders - Year over year growth 2018-2022 (%)
Exhibit 33: Market opportunity by type of respiratory disease
Exhibit 34: Customer landscape
Exhibit 35: Global respiratory drugs market by region - Market share 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Respiratory drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Respiratory drugs market in Americas - Year over year growth 2018-2022 (%)
Exhibit 39: Top three countries in Americas
Exhibit 40: Respiratory drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 41: Respiratory drugs market in EMEA - Year over year growth 2018-2022 (%)
Exhibit 42: Top three countries in EMEA
Exhibit 43: Respiratory drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 44: Respiratory drugs market in APAC - Year over year growth 2018-2022 (%)
Exhibit 45: Top three countries in APAC
Exhibit 46: Market opportunity
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca overview
Exhibit 53: AstraZeneca - Business segments
Exhibit 54: AstraZeneca - Organizational developments
Exhibit 55: AstraZeneca - Geographic focus
Exhibit 56: AstraZeneca - Key offerings
Exhibit 57: GlaxoSmithKline overview
Exhibit 58: GlaxoSmithKline - Business segments
Exhibit 59: GlaxoSmithKline - Organizational developments
Exhibit 60: GlaxoSmithKline - Geographic focus
Exhibit 61: GlaxoSmithKline - Segment focus
Exhibit 62: GlaxoSmithKline - Key offerings
Exhibit 63: Merck overview
Exhibit 64: Merck - Business segments
Exhibit 65: Merck - Organizational developments
Exhibit 66: Merck - Geographic focus
Exhibit 67: Merck - Segment focus
Exhibit 68: Merck - Key offerings
Exhibit 69: Novartis overview
Exhibit 70: Novartis - Business segments
Exhibit 71: Novartis - Organizational developments
Exhibit 72: Novartis - Geographic focus
Exhibit 73: Novartis - Segment focus
Exhibit 74: Novartis - Key offerings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • MORE
Global Respiratory Drugs Market 2018-2022

The author of the report recognizes the following companies as the key players in the global respiratory drugs market: AstraZeneca, GlaxoSmithKline, Novartis, and Merck.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the high cost of respiratory disease management.”

According to the report, one of the major drivers for this market is the increase in incidence and prevalence of different types of respiratory diseases.

Further, the report states that one of the major factors hindering the growth of this market is the patient non-adherence treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll